Background: The outcome of bone and soft tissue sarcomas (BST) after relapse has very
poor prognosis with survival rates less than 39%. Unfortunately there are not many treatment options,
but promising responses have been reported with ifosfamide, etoposide and carboplatin (ICE).
Objective: Therefore, we planned a study for children with recurrent/refractory BST treated with ICE
regimen to evaluate their demographic features, responses to treatment and outcome.
Method: Patients with primary diagnosis of BST and treated with ICE regimen at the time of first or
subsequent relapse, progression or unresponsive disease were selected for study. The files were retrospectively
Results: Thirty of sixty-six patients had metastatic disease at relapse. Patients received median 5 cycles
of ICE and were followed-up median 16.3 months. Overall survival rates were 83% and 62% at
1st and 2nd year. The ORR to the regimen was 43%. Survival rates were significantly higher in good
responders (3-year EFS and OS rates: 50% vs. 8% and 78% vs. 14%; p<0.0001 and p<0.0001). Survival
rates for non-metastatic disease were 42% and 75% for EFS and OS and higher than patients
with metastases at relapse (p<0.001 and p<0.0001). EFS and OS rates of patients with rhabdomyosarcoma
were 42% and 69%. No grade 3 or 4 renal toxicity was documented.
Conclusion: ICE combination improves the outcome of relapsed or refractory sarcomas and it might
serve as second line treatment. Patients with no metastases at relapse would benefit more than others
with metastatic disease.